February 6, 2019
Taiho Pharmaceutical said on February 5 that it has entered into a license agreement with US-based Cullinan Pearl for exclusive worldwide rights, excluding Japan, to develop and commercialize the Japanese company’s investigational novel EGFR tyrosine kinase inhibitor TAS6417. The US...read more